Pfizer has patented isolated engineered immune cells expressing chimeric antigen receptors (CARs) comprising an epidermal growth factor receptor variant 3 (EGFRvIII) binding domain, a transmembrane domain and an intracellular signaling domain claimed to be potentially useful for the treatment of cancer.

Researchers developed three novel non-small cell lung cancer (NSCLC) patient-derived echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion cell lines, including CUTO8 (variant 1), 9 (variant 1) and 29 (variant 3), as well as a fourth ALK-positive cell line, YU1077 (EML4-ALK variant 3).

Gene expression profiles were retrieved from The Cancer Genomic Atlas lung adenocarcinoma (LUAD) cohort (TCGA - LAUD) (n = 567) and association of CYP4B1 with immune inhibitory components was analyzed to better understand the effect of this member of the CYP superfamily on LUAD immune microenvironment.

Researchers aimed to compare the prognostic impact of various inflammatory markers in patients with early-stage lung cancer.

A first-of-its-kind comprehensive map of the network of connections in the human immune system has uncovered previously unknown interactions and filled in gaps in understanding why approved immunotherapies work in some patients and not others.

Novel influenza vaccines with a broader protective spectrum are urgently needed to face viral seasonal variability and epidemic outbreaks.

Several hepatitis A outbreaks have occurred in recent years. Although vaccines exist, effective antivirals against hepatitis A virus (HAV) are lacking, and knowledge gaps remain regarding the viral replication cycle.

Genmab and BioNTech have expanded their global strategic collaboration to develop and commercialize novel immunotherapies for the treatment of cancer. Under the expansion, Genmab and BioNTech will jointly work to research, develop and commercialize novel monospecific antibody candidates for various cancer indications.

In HIV research, scientists are directing their efforts in several directions, attempting to prevent the infection, develop a vaccine, stop infection with the HIV virus progressing to AIDS, and eliminating reservoirs of dormant virus.

BriaCell Therapeutics has secured an exclusive license from University of Maryland, Baltimore County (UMBC) to develop and commercialize soluble CD80 (sCD80) as a biologic agent for the treatment of cancer.